-
Cancer Discovery: Novel immune checkpoint: can be used to enhance T cells against cancer, and also allows CAR-T to fight solid tumors
Time of Update: 2022-04-23
Cancer Discovery PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor ImmunityThe study found that inhibiting protein tyrosine phosphatase 1B (PTP1B) on T cells mobilized the body's immune response to cancer and helped suppress tumor growth .
-
5 common side effects of radiotherapy, how to deal with them?
Time of Update: 2022-04-23
Oral symptomsIf the oral cavity and pharynx are located in the radiotherapy area, most of the oral and pharyngeal mucosal reactions will occur, usually manifested as redness, swelling, ulceration, taste changes, pain, and difficulty swallowing of the oral mucosa .
-
J Clin Oncol: Cabozantinib and Nivolumab Effective in Most Non-Clear Cell Renal Cancers
Time of Update: 2022-04-23
In conclusion, the results of this study suggest that cabozantinib in combination with nivolumab shows a promising therapeutic effect in most non-clear cell renal cancers, especially in the subtype with papillary features , but not in chromophobe Treatment for cell carcinoma is limited .
-
JEADV: Aromatase inhibitors in the treatment of 2 cases of fibrous alopecia on the frontal area of breast cancer patients
Time of Update: 2022-04-23
We report two cases of postmenopausal hormone receptor (estrogen and progesterone)-positive breast cancer patients receiving adjuvant anastrozole who developed frontal fibrous alopecia .
Murad A, Wolinska A, Bergfeld WF,Frontal fibrosing alopecia in breast cancer patients on aromatase-inhibitor: 2 cases.
-
European Radiology: MRI-derived radiomic analysis enables noninvasive assessment of early-stage cervical cancer
Time of Update: 2022-04-23
In conclusion, this study proposes a clinico-radiomic model combining radiomic features and preoperative clinicopathological factors that can predict the probability of clinical adjuvant radiotherapy preoperatively and assist clinical Screening of multimodal therapeutic candidates in patients with early stage cervical cancer .
-
Nat Med: Mental Illness and Self-Injury Burden in Cancer Patients
Time of Update: 2022-04-23
In a study published today in the top medical journal Nature Medicine, researchers estimated the risk of self-harm following a sudden psychiatric diagnosis and the risk of unnatural death following self-harm in 459,542 cancer patients .
-
BMJ: Effects of low-dose CT screening on disease staging and survival in patients with lung cancer
Time of Update: 2022-04-23
The study found that for people aged 55-80 years, the proportion of patients with stage I NSCLC did not change significantly between 2010-13 (27.
Studies have shown that the low-dose CT lung cancer screening program has greatly increased the proportion of patients with stage I NSCLC and prolonged patient survival .
-
Cell sub-issue: Chen Sidi's team uses CRISPR screening to discover new ways to enhance the effect of CAR-T
Time of Update: 2022-04-23
On March 10 , 2022 , the team of Associate Professor of Genetics at Yale University, Sidi Chen , published a paper entitled: A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance Research paper on CAR-T therapy .
-
Clin Cancer Res: The 3-year follow-up survival results of the ATTRACTION-3 study show that nivolumab improves the prognosis of patients with advanced esophageal squamous cell carcinoma (ESCC) compared with chemotherapy
Time of Update: 2022-04-23
Mainly in previously treated patients with advanced esophageal squamous cell carcinoma (ESCC) to compare the efficacy of PD-1 inhibitor nivolu mab (nivolumab) and chemotherapy (paclitaxel or docetaxel) .
-
Nat Rev Clin Oncol: A New Strategy for the Treatment of Advanced Gastrointestinal Stromal Tumors
Time of Update: 2022-04-23
background:background:Gastrointestinal stromal tumor (GIST), the most common form of sarcoma, was first recognized as a distinct pathological entity in the 1990s, and patients with advanced disease have a very poor prognosis due to the lack of effective medical therapy .
-
Nature Cancer: Immunotherapy + mRNA technology to treat triple-negative breast cancer and prevent recurrence
Time of Update: 2022-04-23
Nature Cancer LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancerThe study found that cancer stem cells in triple-negative breast tumors had low expression of ligand-dependent corepressor factor (LCOR), which led to their escape from immunotherapy .
-
Thorac Cancer: Efficacy of carboplatin + albumin-paclitaxel combination in the treatment of recurrent small cell lung cancer (SCLC)
Time of Update: 2022-04-23
Recently, Thoracic Cancer published the results of a phase II clinical study, mainly to evaluate the efficacy and safety of nab-paclitaxel combined with carboplatin after the progression of standard chemotherapy for small cell lung cancer (SCLC) .
-
Int J Urol: Which is better, radical prostatectomy or external radiation therapy + androgen deprivation therapy in patients with clinical T3b prostate cancer?
Time of Update: 2022-04-23
Definite treatments for prostate cancer include radical prostatectomy and External radiation therapy, the optimal treatment of prostate tumors is currently unknown due to the lack of clear and well-defined randomized controlled trialsHere, researchers from Hallym University Dongtan Sacred Heart Hospital in South Korea compared the oncological outcomes of patients with clinical T3b prostate cancer who received either radical prostatectomy (RP) or radiotherapy plus androgen deprivation therapy (HT + RT) .
-
Eur Urol Oncol: Immune milieu and differentiation signatures predict bladder cancer outcome
Time of Update: 2022-04-23
Determined whether immune cell subsets and cancer cell intrinsic characteristics are associated with BC outcome and response to first-line chemotherapyThe researchers used multiplex immunofluorescence (CD3, CD8, FOXP3, CD20, CD68, CD163 and MHC-I) and immunohistochemistry (pancytokeratin, CK5/6, GATA3, PD-1 and PD-L1) on 785 BC patients ( Ta-T4b) primary tumor tissue was examined, and the staining results of the cancerous and stromal portions of the tumor were quantified by digital image analysis .
-
Liver Cancer: Efficacy of lenvatinib with or without drug-eluting microspheres for transarterial chemoembolization in the treatment of unresectable advanced hepatocellular carcinoma
Time of Update: 2022-04-23
Recently, a domestic multi-center team published a real-world study in the journal Liver Cancer, mainly to explore the treatment of unresectable advanced liver disease with lenvatinib combined with or without drug-eluting microspheres transarterial chemoembolization (DEB-TACE).
-
These two new indexes not only reflect the level of personal dietary inflammation, but also increase the risk of breast cancer by more than 150% for those with high scores?
Time of Update: 2022-04-23
This case-control study showed that higher EDII and DIS scores significantly increased BrCa risk, but there was zero association between LIS and BrCa risk in crude and adjusted models .
-
JEADV: Comparison of recurrence rates of basal cell carcinoma treated with different microsurgical techniques
Time of Update: 2022-04-23
This review aimed to assess the recurrence rate of basal cell carcinomas with different MS techniques .
Source: Lacerda PN, Lange EP, Luna NM, Recurrence rate of basal cell carcinoma among different micrographic surgery techniques: Systematic review with meta-analysis.
-
Cell sub-issue: Fudan team finds that bacteria are new hope for the treatment of "the most ferocious breast cancer"
Time of Update: 2022-04-23
In order to further improve the efficacy of precision treatment, the team of Professor Shao Zhimin and Professor Jiang Yizhou of Fudan University Cancer Hospital proposed the " Fudan Classification " in 2019 , and found that there is a unique immunomodulatory subtype ( Immunemodulatory, IM ) in triple-negative breast cancer, and its patients have A more activated immune microenvironment can benefit from immunotherapy .
-
Br J Cancer: Effects of BRAF, KRAS and MSI on cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with metastatic colorectal cancer (mCRC) with peritoneal metastasis (PM)
Time of Update: 2022-04-23
Metastatic with BRAF (mutBRAF) or KRAS mutation (mutKRAS)Colorectal cancer (mCRC) patients have poor prognosis after liver or lung surgery, while the prognostic role of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastases (PM) is unclear .
-
J Clin Oncol: Differences in Adverse Effects of Cancer Treatment Reported by Children with Cancer, Physicians, and Guardians
Time of Update: 2022-04-23
0) with symptomatic adverse reactions reported by children and guardians (according to Red-PRO-CTCAE) .
Lack of Concordance in Symptomatic Adverse Event Reporting by Children, Clinicians, and Caregivers: Implications for Cancer Clinical Trials .